Association between KRAS rs61764370 and triple-negative breast cancer-a false positive?

被引：4
|
作者：
Pharoah, Paul [1 ,2 ]
Antoniou, Antonis [2 ]
Berchuck, Andrew [3 ]
Chenevix-Trench, Georgia [4 ]
Gayther, Simon [5 ]
Goode, Ellen [6 ]
Milne, Roger [7 ]
Sellers, Tom [8 ]
Tyrer, Jonathan [1 ]
机构：
[1] Univ Cambridge, Dept Oncol, Cambridge, England
[2] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England
[3] Duke Univ, Med Ctr, Dept Obstet & Gynaecol, Durham, NC USA
[4] Queensland Inst Med Res, Brisbane, Qld 4006, Australia
[5] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA
[6] Mayo Clin, Coll Med, Dept Hlth Sci Res, Rochester, MN USA
[7] Spanish Natl Canc Res Ctr, Genet & Mol Epidemiol Grp, Madrid, Spain
[8] H Lee Moffitt Canc Ctr & Res Inst, Tampa Bay, FL USA
来源：
LANCET ONCOLOGY | 2011年 / 12卷 / 08期
关键词：
VARIANT;
D O I：
10.1016/S1470-2045(11)70156-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：723 / 724
页数：2
相关论文
共 50 条
  • [1] Association between KRAS rs61764370 and triple-negative breast cancer-a false positive? reply
    Weidhaas, Joanne
    Slack, Frank
    Miller, Nicola
    Harris, Lyndsay
    Tuck, David
    Zhu, Yong
    Zelterman, Daniel
    Kerin, Michael
    Paranjape, Trupti
    Heneghan, Helen
    Lindner, Robert
    Keane, Florence
    Dorairaj, Jemima
    Geyda, Kimberly
    Pelletier, Cory
    Nallur, Sunitha
    LANCET ONCOLOGY, 2011, 12 (08): : 724 - 724
  • [2] No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
    Hollestelle, Antoinette
    van der Baan, Frederieke H.
    Berchuck, Andrew
    Johnatty, Sharon E.
    Aben, Katja K.
    Agnarsson, Bjarni A.
    Aittomaki, Kristiina
    Alducci, Elisa
    Andrulis, Irene L.
    Anton-Culver, Hoda
    Antonenkova, Natalia N.
    Antoniou, Antonis C.
    Apicella, Carmel
    Arndt, Volker
    Arnold, Norbert
    Arun, Banu K.
    Arver, Brita
    Ashworth, Alan
    Baglietto, Laura
    Balleine, Rosemary
    Bandera, Elisa V.
    Barrowdale, Daniel
    Bean, Yukie T.
    Beckmann, Lars
    Beckmann, Matthias W.
    Benitez, Javier
    Berger, Andreas
    Berger, Raanan
    Beuselinck, Benoit
    Bisogna, Maria
    Bjorge, Line
    Blomqvist, Carl
    Bogdanova, Natalia V.
    Bojesen, Anders
    Bojesen, Stig E.
    Bolla, Manjeet K.
    Bonanni, Bernardo
    Brand, Judith S.
    Brauch, Hiltrud
    Brenner, Hermann
    Brinton, Louise
    Brooks-Wilson, Angela
    Bruinsma, Fiona
    Brunet, Joan
    Bruning, Thomas
    Budzilowska, Agnieszka
    Bunker, Clareann H.
    Burwinkel, Barbara
    Butzow, Ralf
    Buys, Saundra S.
    GYNECOLOGIC ONCOLOGY, 2016, 141 (02) : 386 - 401
  • [3] KRAS rs61764370 in Epithelial Ovarian Cancer-Response
    Risch, Harvey A.
    Berchuck, Andrew
    Pharoah, Paul D. P.
    CLINICAL CANCER RESEARCH, 2011, 17 (20) : 6601 - 6601
  • [4] Association between rs61764370, rs9266, and rs140080026 polymorphisms of the KRAS gene and breast cancer risk in a Mexican population
    Gallegos-Arreola, M. P.
    Garcia Verdin, P. M.
    Magana-Torres, M. T.
    Figuera, L. E.
    Zuniga-Gonzalez, G. M.
    Rosales-Reynoso, M. A.
    Gomez-Meda, B. C.
    Puebla-Perez, A. M.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (21) : 6454 - 6464
  • [5] KRAS rs61764370 in Epithelial Ovarian Cancer-Letter
    Weidhaas, Joanne B.
    Slack, Frank J.
    CLINICAL CANCER RESEARCH, 2011, 17 (20) : 6600 - 6600
  • [6] Association of KRAS SNP rs61764370 with risk of invasive epithelial ovarian cancer: Implications for clinical testing
    Berchuck, A.
    Pharoah, P.
    Ramus, S.
    Gayther, S.
    Palmieri, R.
    Pearce, C.
    Couch, F.
    Antonio, A.
    Goode, E.
    Schildkraut, J.
    Chenevix-Trench, G.
    Sellers, T.
    Risch, H.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (02) : S2 - S3
  • [7] rs61764370 polymorphism of Kras and risk of cancer in Caucasian population: A meta-analysis
    Zhang, Shi-Yan
    Shi, Jing
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (02) : 699 - 704
  • [8] The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing
    Pharoah, Paul D. P.
    Palmieri, Rachel T.
    Ramus, Susan J.
    Gayther, Simon A.
    Andrulis, Irene L.
    Anton-Culver, Hoda
    Antonenkova, Natalia
    Antoniou, Antonis C.
    Goldgar, David
    Beattie, Mary S.
    Beckmann, Matthias W.
    Birrer, Michael J.
    Bogdanova, Natalia
    Bolton, Kelly L.
    Brewster, Wendy
    Brooks-Wilson, Angela
    Brown, Robert
    Butzow, Ralf
    Caldes, Trinidad
    Caligo, Maria Adelaide
    Campbell, Ian
    Chang-Claude, Jenny
    Chen, Y. Ann
    Cook, Linda S.
    Couch, Fergus J.
    Cramer, Daniel W.
    Cunningham, Julie M.
    Despierre, Evelyn
    Doherty, Jennifer A.
    Doerk, Thilo
    Duerst, Matthias
    Eccles, Diana M.
    Ekici, Arif B.
    Easton, Douglas
    Fasching, Peter A.
    de Fazio, Anna
    Fenstermacher, David A.
    Flanagan, James M.
    Fridley, Brooke L.
    Friedman, Eitan
    Gao, Bo
    Sinilnikova, Olga
    Gentry-Maharaj, Aleksandra
    Godwin, Andrew K.
    Goode, Ellen L.
    Goodman, Marc T.
    Gross, Jenny
    Hansen, Thomas V. O.
    Harnett, Paul
    Rookus, Matti
    CLINICAL CANCER RESEARCH, 2011, 17 (11) : 3742 - 3750
  • [9] Study on mouse model of triple-negative breast cancer: association between higher parity and triple-negative breast cancer
    Chun Huang
    Xuan Wang
    Baocun Sun
    Man Li
    Xiulan Zhao
    Yanjun Gu
    Yanfen Cui
    Yan Li
    Targeted Oncology, 2015, 10 : 85 - 97
  • [10] Study on mouse model of triple-negative breast cancer: association between higher parity and triple-negative breast cancer
    Huang, Chun
    Wang, Xuan
    Sun, Baocun
    Li, Man
    Zhao, Xiulan
    Gu, Yanjun
    Cui, Yanfen
    Li, Yan
    TARGETED ONCOLOGY, 2015, 10 (01) : 85 - 97
12345